Evaluation Reports Archive

The following Evaluation reports have been archived and are no longer available as downloads from this website. If you would like to have access to any of the documents listed please contact nuth.nyrdtc.rxsupp@nhs.net.

<< Return to the list of current Evaluation Reports

Document Published
Adefovir dipivoxil in chronic hepatitis B infection (N) Jun 04
Alemtuzumab in chronic lymphocytic leukaemia Mar 07
An update on newer agents for the treatment of pulmonary hypertension Mar 04
Aromatase inhibitors in early stage breast cancer (N) Mar 07
Bevacizumab in metastatic breast cancer (N) Sep 07
Bortezomib second-line in multiple myeloma (N) Mar 06
Docetaxel or paclitaxel in early stage breast cancer (N) Mar 06
Drotrecogin alfa (activated) in severe sepsis (N) Dec02
Entecavir in chronic hepatitis B (N) Apr 07
Erlotinib in non-small cell lung cancer Mar 06
Ibandronic acid in hypercalcaemia of malignancy, bone pain and the prevention of skeletal events associated with skeletal metastases Aug 05
Ibritumomab in b-cell follicular non-hodgkin’s lymphoma Mar 06
Natalizumab in multiple sclerosis (N) Mar 07
Omalizumab in severe persistent allergic asthma (N) Jun 06
Palonosetron for the prevention of nausea and vomiting associated with cancer chemotherapy Mar 07
Pegvisomant in acromegaly Jan 06
Pemetrexed in malignant pleural mesothelioma (N) Mar 06
Rituximab in combination with cvp chemotherapy for the management of follicular non-hodgkin’s lymphoma Mar 06
Teriparatide in osteoporosis (N) Jul 04